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SomaticPTPN11mutations cause juvenile myelomo-
nocytic leukemia (JMML). Germline PTPN11 defects
cause Noonan syndrome (NS), and specific inherited
mutations cause NS/JMML. Here, we report that he-
matopoietic cells differentiated from human induced
pluripotent stem cells (hiPSCs) harboring NS/JMML-
causing PTPN11 mutations recapitulated JMML
features. hiPSC-derived NS/JMML myeloid cells ex-
hibited increased signaling through STAT5 and upre-
gulation of miR-223 and miR-15a. Similarly, miR-223
and miR-15a were upregulated in 11/19 JMML bone
marrow mononuclear cells harboring PTPN11 muta-
tions, but not those without PTPN11 defects.
Reducing miR-223’s function in NS/JMML hiPSCs
normalized myelogenesis. MicroRNA target gene
expression levels were reduced in hiPSC-derived
myeloid cells as well as in JMML cells with PTPN11
mutations. Thus, studying an inherited human cancer
syndromewith hiPSCs illuminated early oncogenesis
prior to the accumulation of secondary genomic
alterations, enabling us to discover microRNA dysre-504 Cell Reports 13, 504–515, October 20, 2015 ª2015 The Authorsgulation, establishing a genotype-phenotype associ-
ation for JMML and providing therapeutic targets.INTRODUCTION
Juvenile myelomonocytic leukemia (JMML), an aggressive, diffi-
cult-to-treat myelodysplastic and myeloproliferative neoplasm
of early childhood, is characterized by excessive proliferation
of monocytic and granulocytic cells along with dysplastic fea-
tures. Most JMML cases are associated with somatic gain-of-
function (GOF) mutations in components of the RAS/MAPK
signal transduction pathway (Yoshida et al., 2012). A minority
of cases arise in young children with Noonan syndrome (NS;
OMIM: 163950), a genetic disorder with increased RAS/MAPK
signaling (Tartaglia and Gelb, 2008). 50% of NS patients and
35% of JMML cases carry GOF PTPN11 mutations altering
SHP-2. However, the molecular mechanisms through which
PTPN11 mutations result in deranged myelopoiesis are not
well understood.
SHP-2 is a member of the tyrosine phosphatase family and
regulates several biological processes, particularly embryogen-
esis and hematopoietic cell development (Tartaglia and Gelb,
2008). For NS, particular germline mutations in PTPN11 underlie
JMML,which has clinical features similar to those in childrenwith
Figure 1. Clinical Features of NS/JMML hiPSC-Derived Hematopoietic Cells
(A) Hematopoietic growth factor dose-response curves to GM-CSF. Values are the mean ± SEM for three independent experiments. At 0.01 ng/ml GM-CSF,
**p% 0.01 in NS/JMML patient #4 versus CTRL. At 0.1 ng/ml GM-CSF, **p% 0.01 in NS/JMML patients #3 and #4 versus CTRL.
(B) Representative pictures of CFU-GM from study of hypersensitivity to GM-CSF. Scale bars represent 200 mm.
(C) Colony-forming capacity. Bar graphs represent mean ± SEM of three independent experiments. The CTRL group consisted of hiPSC lines, each derived from
different healthy individuals.
(D) Representative images of CFU-GM and BFU-E colonies and Wright-Giemsa staining after cytospin. Scale bars represent 200 mm for colonies and 20 mm for
cytospin analysis.
(legend continued on next page)
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JMML arising from somatic mutations in PTPN11, although with
generally better outcomes. Mutations in PTPN11, RAS genes,
NF1, and CBL are mutually exclusive in JMML, suggesting that
one hit in this pathway is sufficient for leukemogenesis (Tartaglia
and Gelb, 2008; Pe´rez et al., 2010; Yoshida et al., 2012).
The ability to induce human induced pluripotent stem cells
(hiPSCs) from terminally differentiated cells such as skin fibro-
blasts (Takahashi et al., 2007) provides an opportunity to study
disease pathogenesis. For hereditary disorders associated
with cancer such as NS/JMML, hiPSCs derived from non-
cancerous cells permit investigation of the role of the inherited
mutations per se, free of secondary or additional genomic alter-
ations that frequently occur during cancer evolution and that
might obscure studies performed with hiPSCs derived from the
cancer cells (Kotini et al., 2015). Here, we report our findings
from modeling JMML using hiPSCs derived from subjects
with NS/JMML and NS without leukemia harboring PTPN11
mutations.
RESULTS
Generation of hiPSCLines andClinicalManifestations in
NS/JMML-Derived Hematopoietic Cells
Using somatic cell reprogramming (Takahashi et al., 2007), we
obtained hiPSC lines from skin fibroblasts harboring mutations
in PTPN11 from two subjects with NS/JMML. As controls, we
used five hiPSC lines derived from skin fibroblasts of unrelated
healthy individuals and two subjects with NS, the latter to clarify
which perturbations were attributable to the PTPN11GOFmuta-
tions generally versus those specific to JMML pathogenesis
(Tables S1 and S2). All PTPN11 mutations resided in the
N-SH2 domain, destabilizing SHP-2’s inactive conformation.
Pluripotency was established based on in vitro characteristics
(Figures S1A and S1B) and in vivo teratoma formation (Fig-
ure S1C). All hiPSC lines had a normal karyotype (Figure S1C).
NS and NS/JMML hiPSCs retained heterozygosity for their
PTPN11 mutation (Figure S1F). Transgenes were integrated at
one to four sites and were silenced (Figures S1D and S1E). After
EGF stimulation, ERK activation was increased and sustained in
the NS and NS/JMML hiPSC lines (Figure S1G), consistent with
PTPN11 mutation GOF effects.
Following an established protocol using a cocktail of cytokines
(IGF-1, VEGF, EPO, IL-11, IL-3, IL-6, bFGF, SCF, and TPO) (Gri-
goriadis et al., 2010; Kennedy et al., 2007) (Figures S1H and S2A;
Supplemental Experimental Procedures), hiPSC lines were
differentiated into hematopoietic progenitor lineages, showing
typical morphology for the various cell types (Figure S1H). Flow
cytometry analysis showed that the differentiating lines ex-
pressed the pan-hematopoietic marker CD45 at least until day
28 (Figure S2B). Neither the B-lymphocyte antigen CD19 nor
the T cell surface glycoprotein CD3 gamma chain (CD3G) was
detected at day 14 (Figures S2C and S2D). Thus, we were able
to obtain hematopoietic cells without lymphocyte lineages.(E) Flow cytometry of hematopoietic cells shown as percentage of positive cells
The CTRL group represents four healthy individuals, the NS group represents the
NS/JMML subjects. Box-and-whisker plots show the median to the first and thi
dependent experiments. See also Figure S3.
506 Cell Reports 13, 504–515, October 20, 2015 ª2015 The AuthorsTo analyze seminal features of JMML, we used differentiating
cells at day 14 after embryoid body (EB) formation. GM-CSF
hypersensitivity was observed in the number of colonies
formed from NS/JMML hematopoietic cells relative to controls
(Figure 1A). Exposure of NS/JMML hematopoietic cells in
semi-solid media to low concentrations of GM-CSF (0.01 or
0.1 ng/ml) produced larger colonies compared to controls
or NS (Figure 1B). Fluorescence in situ hybridization with
a dual probe showed an absence of the BCR-ABL fusion
(Figure S3A).
Next, we performed colony-forming unit (CFU) assays inmeth-
ylcellulose and a cocktail of cytokines to determine the prolifer-
ative capacity of the different hematopoietic progenitors. We
observed a 10-fold increase in the total number of colonies form-
ing from 1.53 104 NS/JMML cells compared to those from com-
parable numbers of control or NS cells, which were attributable
to increases among the CFU-erythroid (CFU-E), burst-forming
unit-erythroid (BFU-E), and CFU-granulocyte/macrophage
(CFU-GM) subtypes (Figure 1C). Moreover the NS/JMML granu-
locyte-macrophage colonies were notably larger (Figure 1D).
Cytospin analysis confirmed the granulocyte/monocyte and
erythroid cell morphology in the CFU-GM and BFU-E colonies,
respectively (Figure 1D).
To characterize the types of myeloid cells differentiating from
hiPSC lines, cell populations were analyzed using flow cytome-
try. We observed a significantly greater number of CD33+
myeloid cells at day 14 in NS/JMML lines compared to the
control and NS lines (Figure 1E), a difference that persisted
(Figure S3B). We observed increased numbers of all leukocytes
(CD33+/CD45+), monocytes/granulocytes (CD11B+ and CD14+),
and erythroid cells (CD71+/CD235a+) (Figure 1E) among the NS/
JMML-derived cultures compared to controls and NS groups.
The NS/JMML megakaryocyte population was similar to the
control and NS samples (Figure 1E).
Taken as a whole, hematopoietic progenitor cells derived from
NS/JMML hiPSC lines recapitulated the principal features of
JMML, including GM-CSF hypersensitivity and a myeloid popu-
lation that was increased and hyper-proliferative.
NS/JMML-Derived CD33+ Myeloid Cells Show
Dysregulation in Major Biological Processes
We compared the transcriptome profiles among hiPSC and
sorted CD33+ myeloid cells from control and patient samples.
Hierarchical clustering and principal component analysis
(16,380 genes significantly different between hiPSCs and
CD33+ myeloid cells) revealed comparable patterns among the
control, NS, and NS/JMML hiPSC lines (Figures 2A and 2B).
The transcriptome profiles of CD33+ myeloid cells, which were
highly reproducible and differed from those of the hiPSCs
(Figures 2A–2D), revealed consistently decreased pluripotency
gene expression and upregulation of genes related to myeloid
regulation (Figures 2C and 2D), further evidence of successful
myelopoiesis.for myeloid surface markers.
two Noonan syndrome patients, and the NS/JMML group represents the two
rd quartiles and the minimum and maximum values. Values represent four in-
(legend on next page)
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Genotype-specific dysregulation of genes related to biological
processes such as metabolism, development, and proliferation
was observed in CD33+ myeloid cells using Gene Ontology
(GO) classification (Figure 2E). Gene set enrichment analysis
(GSEA) comparing control and NS/JMML CD33+ myeloid cells
also revealed significant differences among gene lists related
to receptor tyrosine kinase signaling pathways, cell cycle, and
myeloid leukemias (Figure 2F). NS and NS/JMML samples
differed for gene lists relevant for cell cycle andmyeloid leukemia
(Figure S4). At the protein level, we found that total and activated
(phosphorylated) STAT5, a critical component of the JAK-STAT
signaling pathway implicated in JMML pathogenesis (Kotecha
et al., 2008), were vastly increased in the NS/JMML CD33+
myeloid cells as compared to control CD33+ myeloid cells
(Figure 2G); STAT5 activation in NS myeloid cells was intermedi-
ate. ERK activation was increased basally and after GM-CSF
stimulation in the PTPN11-mutant CD33+ myeloid cells, being
the highest in NS/JMML CD33+ myeloid cells (Figure 2H).
GSEA also revealed upregulation of CDKN1A (p21) and MYC
in NS/JMML CD33+ myeloid cells. Although their levels (Fig-
ure 2I) were comparable between NS and NS/JMML, con-
tributions from others cell-cycle regulators were suggested
(Figure S4).
We assessed apoptosis and proliferation rates in the CD33+
myeloid cells using Annexin V and Ki67 staining, respectively.
As compared to controls, NS/JMML CD33+ myeloid cells
showed similar early-stage apoptosis but 8-fold increased
proliferation (Figures 2J and 2K). Proliferation of NS CD33+
myeloid cells was increased, but not to the level observed in
NS/JMML.
miR-223 and miR-15a Are Dysregulated in PTPN11
Mutant JMML Myeloid Cells
We assessed expression levels of mature microRNAs (miRNAs)
relevant to hematopoiesis and cancer in the hiPSC-derived
CD33+ myeloid cells (Chen et al., 2004; Ramkissoon et al.,
2006; Vasilatou et al., 2010). While the levels of several miRNAs
were not different, miR-223 and miR-15a expression levels were
increased in NS/JMML 50- and 10-fold, respectively (Figures 3A
and 3B). This miRNA upregulation was cell-type specific as
levels of those two miRNAs were at most subtly increased in
the parental hiPSC lines (Figure 3C).
To confirm the relevance of our in vitro findings for JMML
in vivo, miR-223 and miR-15a expression levels were measuredFigure 2. Profiling Analyses in CD33+ Myeloid Cells and Specific Dysreg
(A andB) Principal component analysis and unsupervised hierarchical clustering o
cells.
(C and D) Heatmaps of 67 myeloid differentiation genes and 13 pluripotent
downregulated).
(E) GO analysis of upregulated genes altered in CD33+ myeloid patients versus c
(F) GSEA curves in CD33+ myeloid NS/JMML cells versus controls. JAK-STAT a
leukemia, and cell cycle (red, upregulated; blue, downregulated).
(G and H) Representative immunoblots show increased pSTAT5 and total STAT5
Lanes were run on the same gel but were noncontiguous.
(I) CDKN1A and MYC expression levels in CD33+ myeloid cells. Bar graphs repre
(J and K) Annexin V (J) and Ki-67 (K) staining of CD33+ myeloid cells show apop
Bar graphs represent mean ±SEM. TheCTRL group consisted of hiPSC lines, eac
separate experiments. See also Figure S4.
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with JMML harboring PTPN11, KRAS, NRAS, or CBLmutations,
with or without NS, as well as from controls (children in remission
from acute leukemia) (Table S3). miR-223 and miR-15a levels
were significantly increased among patients with germline or so-
matic PTPN11mutations compared to controls (Figure 3D). 11 of
19 JMML bone marrow mononuclear cells with PTPN11 muta-
tions (58%) showed increased expression of miR-223 and/or
miR-15a, eight being increased for both. In contrast, miR-223
and miR-15a levels were not increased in the bone marrow
mononuclear cells from patients with JMML with other RAS
pathway somatic mutations.
Upregulation of miR-223 Is Necessary and Sufficient for
JMML-Associated Abnormal Myelopoiesis
To determine if upregulation of miR-223 and miR-15a were
necessary for the abnormal myelopoiesis observed in NS/
JMML, we reduced their function using molecular decoys
(Mullokandov et al., 2012). hiPSCs infected with decoy lenti-
virus expressing GFP retained pluripotency (Figure 4A). The
majority of cells after hematopoietic differentiation continued
to express GFP (Figure 4A, bottom row), indicating the
presence of the decoy. In the miR-223 decoy-treated cells, the
percentage of CD33+/GFP+ myeloid cells was significantly
decreased in NS/JMML, achieving a level comparable to that
observed with decoy-untreated control hiPSCs (Figure 4B).
miR-15a decoy treatment did not alter the production of
CD33+ cells (Figure 4C).
Next, we sought to determine whether reduction of miR-223
rescued the GM-CSF hypersensitivity and hyper-proliferation of
the NS/JMML myeloid progenitors. Using a low concentration
of GM-CSF (0.01 ng/ml), we observed a significant decrease
in the number of colonies arising from the miR-223 decoy-
treated NS/JMML cells as compared to untreated ones (Fig-
ure 4D). Compared to the control hiPSC-derived cells, the
rescue of the GM-CSF hypersensitivity was partial. Using
colony-formation assays, we observed a decrease of the
CFU-GM colony subtype in miR-223 decoy-treated NS/JMML
cells (Figure 4E).
To determine whether upregulation of miR-223 was sufficient
to perturb myelopoiesis, control hiPSCs were infected with lenti-
virus expressing miR-223 (Baccarini et al., 2011). This vector
expresses a pri-miR-223 transcript within an intron, which is up-
stream of a reporter encoding a truncated nerve growth factorulated Pathways and Proliferation in NS/JMML CD33+ Myeloid Cells
f genome-wide expression profile of hiPSCs and hiPSC-derived CD33+myeloid
genes in hiPSC lines and CD33+ myeloid cells (orange, upregulated; blue,
ontrols.
nd MAPK signaling pathways, chronic myelocytic leukemia, acute myelocytic
(G) and pERK (H) protein expression levels in NS/JMML CD33+ myeloid cells.
sent mean ± SEM.
tosis and proliferation, respectively.
h derived from different healthy individuals. Data represent a composite of three
Figure 3. Increased Expression Levels of miR-223 and miR-15a in NS/JMML CD33+ Cells
(A) Expression level of miR-181, miR-128a, miR-17, miR-20a, and miR-106 in CD33+ myeloid cells derived from hiPSCs.
(B) Expression level of miR-223 and miR-15a in CD33+ myeloid cells derived from hiPSCs.
(C) qRT-PCR analysis of miR-223 and miR-25a in hiPSC lines. Expression levels were normalized to U6 and relative to CTRL sample. Bar graphs represent
mean ± SEM. Data represent a composite of three separate experiments.
In (A)–(C), the CTRL group consisted of hiPSC lines, each derived from different healthy individuals.
(D) qRT-PCR showed the upregulated expression pattern of miR-223 and mirR-15a in bone marrow cells from six controls and 26 JMML patients harboring
PTPN11, KRAS, NRAS or CBL mutations, with or without NS (Table S3). The red squares represent JMML patients harboring PTPN11 mutations with NS and
black squares represent JMML harboring PTPN11 mutations patients without NS. Dot plots represent mean ± SEM.receptor (NGFR). Pluripotency of the successfully infected
hiPSCs was confirmed (Figure 4F). Overexpression of miR-223
in control and NS hiPSCs resulted in a 10%–12% increase of
the CD33+/NGFR+ population compare to those cells infected
with the same lentiviral construct without miR-223 (Figure 4G).
Moreover, we observed increased GM-CSF sensitivity andCincreased numbers of CFU-GM colonies in control hemato-
poietic cells overexpressing miR-223 (Figures 4H and 4I). Since
overexpression of miR-223 alone upregulated myelopoiesis
in control hiPSCs, we concluded that PTPN11 mutation-driven
upregulation of miR-223 is sufficient to drive this aspect of
JMML.ell Reports 13, 504–515, October 20, 2015 ª2015 The Authors 509
Effects of miR-223 and miR-15a Upregulation on mRNA
Levels in JMML
One of the major mechanisms by which miRNAs’ reduce protein
expression is targeted degradation of mRNAs. To determine
relevant targets of miR-223 and miR-15a in JMML, we per-
formed an integrated analysis to look for reduced steady-state
expression levels among genes predicted to be their targets in
hiPSC-derived CD33+ myeloid cells (Figure S5A). Comparisons
of expression among control and NS/JMMLCD33+myeloid cells
revealed a significant number of potential miR-223 and miR-15a
mRNA targets with reduced expression levels (Figure S5B). Per-
mutation testing revealed that the number of putative miR-15a
mRNA targets with reduced expression level was significantly
greater than expected by chance (Figure S5C). Reduced levels
of putativemiR-223 targets were also observed but did not reach
statistical significance. The set of genes predicted to be targets
for both miRNAs was the most strikingly enriched.
To choose genes with the highest probability of being true tar-
gets of one or both of these miRNAs, calculations of thermody-
namic accessibility and gene functionwere combined (Table S4).
The lower steady-state levels of six putative target genes, two
each from the miR-223 only, miR-15a only, and miR-223/miR-
15 groups, were confirmed using RT-PCR (Figure 5A).
To establish genes that were bona fide targets of miR-223, we
leveraged an in vitro system using HEK293 cells stably express-
ing miR-223 constitutively (called HEK293-miR223 hereafter)
(Baccarini et al., 2011). Of note, native HEK293 cells do not
express miR-223. We generated constructs containing the
30 UTR of miR-223 putative targets, RAB12 and FOXO3,
including their putative miRNA target andmutated sites, inserted
downstream of the firefly luciferase gene (Table S5). Expression
of miR-223 with these 30 UTRs reduced luciferase expression
50%,whichwas statistically significant (Figure 5B) and compa-
rable to that observed in a previous study that established LMO2
and CEBP-b as miR-223 targets involved in myeloid cell devel-
opment (Sun et al., 2010). We also confirmed that LMO2 and
CEBP-b steady-state mRNA levels were reduced in NS/JMML
CD33+ cells (Figure S5D). Mutations in the miR223-binding sites
resulted in significantly less degradation of the 30 UTR gene tar-
gets and sequence-specific suppression (Figure 5B). Taken as a
whole, these results indicated that RAB12 and FOXO3 are true
targets of miR-223.
We leveraged the identification of bona fide targets of miR-223
to document the functional effects of themiR-223 decoy. Reduc-
tion of miR-223 function with the decoy would be predicted to in-
crease the steady-state mRNA levels of miR-223 target genes,
which is what was observed for RAB12 and FOXO3 in NS/
JMML CD33+ myeloid cells (Figure S5E).
Finally, we examined the steady-state expression levels of
13 putative and proven miR-223 and miR-15 target genes in
PTPN11 and non-PTPN11 mutant JMML and control bone
marrow mononuclear cells. Among those, nine (FOXO3, SPTB,
NPM1, WHSC1K1, DICER1, MTL5, RAB12, SMAP1, and
SHROOM4) were significantly reduced in PTPN11 mutant
JMML (Figures 5C and S5F). Of note, these results sug-
gest that the dysregulation of these genes are specific
to PTPN11-associated JMML. Moreover, gene expression
was similarly reduced among samples from patients with in-510 Cell Reports 13, 504–515, October 20, 2015 ª2015 The Authorsherited and somatic PTPN11 mutations, suggesting similar
JMML pathogenesis.
DISCUSSION
In general, JMML remains a lethal disorder, and progress in
treatment has been hindered by the lack of a robust model
with which to study it. Taking this into account, our study repre-
sents an important advance in our understanding of JMML
pathophysiology, providing a valuable model in the context of
RASopathies, for several reasons. First, we used hiPSC technol-
ogy as an alternative model for studying a myeloproliferative and
myelodysplastic disorder, and our study had the key feature that
it began with a non-hematopoietic cell type, skin fibroblasts.
Although the hiPSCs used for our study harbored an activating
RAS/MAPK pathway mutation, they should not have selected
for secondary genomic alternations contributing to hemato-
poietic disease. A previous hiPSC study used circulating
cancerous cells from two JMML patients (Gandre-Babbe et al.,
2013). While valuable, this approachmay not capture the earliest
stages of JMML leukemogenesis. Here, we were able to estab-
lish hiPSC lines from NS and NS/JMML patients with germline
mutations in specific residues of PTPN11 and then differentiate
them into hematopoietic lineages to recapitulate seminal fea-
tures of JMML. This study demonstrated that the pre-existing
PTPN11 GOF mutations were sufficient to drive key features of
this leukemogenesis. Moreover, NS- and JMML-associated
PTPN11 missense mutations result in increased SHP-2 phos-
phatase activity, leading to increased ERK activation (Araki
et al., 2004; Fragale et al., 2004). Similarly, ERK hyperactivation
was present in our patient-derived hiPSCs as well as in the
CD33+myeloid cells differentiated from them. JMML-associated
somatic PTPN11 mutations (E76K, D61V, and D61Y) induce he-
matopoietic progenitor hypersensitivity to GM-CSF (Chan et al.,
2005; Mohi et al., 2005). Similarly, our study showed that in-
herited PTPN11 NS/JMML-associated mutations (D61H and
G503R) induced GM-CSF hypersensitivity. In contrast, the two
PTPN11 mutations associated only with NS, Y63C and E76D,
caused at most minimal GM-CSF hypersensitivity. In addition,
the observation of STAT5 hyper-activation in the NS/JMML
hiPSC-derived CD33+ myeloid cells suggested that increased
STAT5 signalingmay play a role in NS/JMML as it does in somat-
ically acquired JMML (Kotecha et al., 2008). Our findings were
also consistent with the observation that bone marrow cells
from children with NS and transient myeloproliferative disorder
are less responsive to STAT5 than similar cells from children
with JMML (Kotecha et al., 2008). Taken together, our results
provide further evidence that there is biological specificity and
a severity gradient for the hematological defects underlying
NS/JMML, arising from the degree of SHP-2’s destabilization,
its interactions with signaling partners, or PTPase-independent
roles of SHP-2 (Tartaglia and Gelb, 2008). From a clinical point
of view, this finding would suggest that genetic differences in
PTPN11 encoded in the germline may explain why only a small
percentage of NS patients get JMML.
Second, this study elaborated on the roles of miR-223 and
miR-15a and their targets in mediating the JMML phenotype.
Over the past decade, the study of miRNAs in leukemias has
(legend on next page)
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established the importance of these regulators for diagnosis, as
prognostic factors, and as therapeutic targets (Mian and Zelez-
nik-Le, 2010). It is worth noting that the upregulation of miR-
223 and miR-15a in nearly 60% of the JMML patients harboring
PTPN11 mutations may facilitate subclassification of this disor-
der. Moreover, JMML outcomes have previously been shown
to be worse when somatic PTPN11 mutations were the RAS
pathway drivers (Yoshida et al., 2009). Our work provides a
specific molecular mechanism that might explain that clinical
difference and creates opportunities for developing targeted
therapies. Specifically, inhibitors and regulators of miR-223
could be used to treat JMML involving dysregulation of the
RAS/MAPK pathway. In addition, miR-223 and/or miR-15a
target genes, which were downregulated in the NS/JMML
CD33+ myeloid cells as well in bone marrow samples from
JMML patients with PTPN11mutations, could also be leveraged
to develop new therapies.
In summary, our present study showed dysregulation in
myeloid cells derived from NS/JMML hiPSCs and elucidated a
molecular mechanism underlying aspects of JMML in the
context of NS, identifying upregulation of two miRNAs as poten-
tial biomarkers in JMML bone marrow mononuclear cells. Their
upregulation distinguished JMML caused by PTPN11mutations
from other genetic forms of the disease.
EXPERIMENTAL PROCEDURES
Generation of hiPSC Lines and Myeloid Differentiation
Dermal biopsies and bonemarrow aspirates were takenwith informed consent
and institutional review board approval. Fibroblasts were reprogrammed
based on a protocol using retroviruses expressing separately human
c-MYC, OCT3/4, SOX2, and KLF4 (Figure S1; Table S1) (Carvajal-Vergara
et al., 2010). To induce differentiation, EBs were generated in six-well, ultra-
low-attachment plates in differentiation media consisting of a basic media
with different cytokines as described previously (Figure S2) (Grigoriadis
et al., 2010; Kennedy et al., 2007). See also Supplemental Experimental Pro-
cedures for more details.
Flow Cytometric, Cell Sorting, Apoptosis, and Proliferation Assays
Flow cytometric analyses were performed at day 14 of differentiation on he-
matopoietic cells harvested from dissociated EBs (Table S2). Cells were
stained in PBS and 2% fetal bovine serum (FBS) with primary antibodies
against CD45, CD14, CD33, CD11b, CD71, CD235a, and CD41 (BD Pharmin-
gen), and analyzed on an LSR-II (BD Biosciences). Apoptosis and proliferation
were quantified as CD33+ cells that were Annexin V+/Death dye- (PerCP-Cy;
BD Pharmingen and Blue Pacific Invitrogen) and Ki67+ (BD Pharmingen),
respectively. Data were analyzed using FlowJo software, version 7.6.Figure 4. Functional Analyses for miR-223 and miR-15a Using Decoys
(A) GFP and immunofluorescence for OCT3/4 in infected hiPSCs with lentivirus c
fluorescence in differentiated EBs containing a decoy construct for miR-223 or m
(B and C) Flow cytometry analysis for CD33+ in GFP+ knocked-down cells (p < 0.0
and the minimum and maximum values. The CTRL group consisted of hiPSC lin
(D) Number of CFU-GM colonies treated with 0.01 ng/ml GM-CSF in hiPSCs unt
(E) Decreased colony formation capacity in hematopoietic progenitors derived fro
(F) Representative immunofluorescence for NGFR and OCT3/4 in hiPSCs infec
expression miR-223). Scale bars represent 400 mm.
(G) Flow cytometry analysis for CD33+/NGFR+ overexpressed miR-223 cells or w
plots show the median to the first and third quartiles and the minimum and maxi
(H) Number of CFU-GM colonies treated with 0.01 ng/ml GM-CSF in hiPSCs exp
(I) Increased colony formation capacity in hematopoietic progenitors derived from
Bar graphs represent mean ± SEM (p < 0.05 for all). Data represent a composite
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For cytokine sensitivity assays, hematopoietic cells (Table S2) were plated
at 2 3 104 in methylcellulose (MethoCult H4531, STEMCELL Technologies)
with escalating concentration of GM-CSF (0.01, 0.1, 1, and 10 ng/ml)
(R&D Systems) or 1.5 3 104 in methylcellulose containing agar leukocyte
conditioned medium (Agar-LCM), formulated to support the growth of
granulocyte and macrophage progenitors. The hypersensitivity to GM-
CSF was observed in a dose-response curve, represented as percentage
of maximal colony formation and calculated by dividing the number of
colonies at each GM-CSF concentration by the average number of colonies
at GM-CSF 10 ng/ml (Table S2). For decoy and overexpression miR-223
assays, the treated hematopoietic cells were plated at 2 3 104 with
0.01 ng/ml GM-CSF (Table S2). After 14 days at 37C in humidified 5%
CO2, myeloid colonies were counted. For clonogenic myeloid progenitor
assays, MethoCult H4435 Enrich (STEMCELL Technologies) was used.
Fourteen days after plating, myeloid and erythroid colonies were counted
based on standard guidelines previously described (Nissen-Druey et al.,
2005). Cell morphology was assessed using a Cytospin 3 cytocentrifuge
(Thermo Fisher Scientific) and staining with Giemsa (Accustain, Sigma-
Aldrich).
Treatment with GM-CSF and Immunoblotting
Flow-sorted CD33+ cells were treated with GM-CSF (1 ng/ml) for 15 min
at 37C (Table S2). The 937 cell line was used as a control for STAT5
phosphorylation assays (10 ng/ml GM-CSF). Cells were lysed with RIPA
buffer containing protease and phosphatase inhibitors. Blots were probed
with antibodies to p-STAT5 (1:250, BD Pharmingen), STAT5 (1:1,000, Cell
Signaling Technology), p-ERK1/2 T202/Y204 (1:2,000, Cell Signaling),
ERK1/2 (1:2,500, Santa Cruz Biotechnology), and b-actin (1:10,000,
Sigma-Aldrich) (loading control). To measure ERK levels in undifferentiated
hiPSCs, the cells were treated with 10 ng/ml hEGF for 0, 5, 15, and 60 min
at 37C.
miRNA qRT-PCR
miRNA expression levels were quantified in total RNA from sorted CD33+ cells
isolated using Trizol and MiRNase kit (QIAGEN) (Table S2). TaqMan human
miRNA assays were used to quantify mature miRNA expression levels as pre-
viously described (Chen et al., 2005). U6 (Applied Biosystems) was used as the
endogenous control. Reverse-transcriptase reactions contained 10 ng of total
RNA, 50 nM reverse transcription (RT) primer, 1x RT buffer, 0.25 mM each of
dNTPs, 3.33 U/ml MultiScribe reverse transcriptase and 0.25 U/ml RNase in-
hibitor. The 7.5 ml reactions were incubated in an Applied Biosystems 9700
Thermocycler in a 96-well plate for 30 min at 16C, 30 min at 42C, and
5 min at 85C and then held at 4C. All reverse-transcriptase reactions were
run in triplicate. Real-time PCR was performed using a standard TaqMan
PCR kit protocol on an Applied Biosystems 9700 Thermocycler. The 10 ml
PCR included 0.67 ml RT product, 1x TaqMan Universal PCR Master Mix,
and 0.2 mM TaqMan probe. The reactions were incubated in a 96-well plate
at 95C for 10 min, followed by 40 cycles of 95C for 15 s and 60C for
1 min. All reactions were run in triplicate. All TaqMan miRNA assays are avail-
able through Applied Biosystems.and Overexpression
ontaining a decoy construct for miR-223 or miR-15a. Bottom row shows GFP
iR-15a. Scale bars represent 400 mm.
5 for all). Box-and-whisker plots show the median to the first and third quartiles
es, each derived from different healthy individuals.
reated and treated-decoy miR-223 (p < 0.05 for all).
m NS/JMML hiPSCs containing a decoy construct for miR-223 (p < 0.05 for all).
ted with a lentiviral construct overexpressing miR-223 (up-miR-223 = over-
ithout miR-223 (EMPTY = without miR-223) (p < 0.05 for all). Box-and-whisker
mum values. Data represent a composite of three separate experiments.
ressing miR-223 or not (p < 0.05 for all).
NS/JMML hiPSCs containing a miR-223 overexpression construct.
of three separate experiments.
Figure 5. miR-223 and miR-15a Target Genes: Validation in hiPSC-Derived CD33+ Cells and Expression Levels in Bone Marrow Cells from
JMML Patients
(A) Confirmation of the expression level of selected miR-223 and miR-15a target genes in CD33+ cells using qRT-PCR. Bar graphs represent mean ± SEM
(p < 0.05 for all).
(B) Luciferase activity of HEK293T cells or HEK293T cells overexpressing miR-223 transfected with a plasmid encoding luciferase without any 30 UTR sequence
(pMIR.Report.Vector) and luciferase upstream of theRAB12 and FOXO3 30 UTR normal andmutated sequences (p < 0.05 for all) (Table S5). Bar graphs represent
mean ± SEM.
(C) Gene expression levels of targets for miR-223, miR-15a, and both miRNAs in bone marrowmononuclear cells from JMML patients harboring PTPN11, KRAS,
NRAS, and CBLmutations (p < 0.05 for all). Red and black squares represent JMML samples with or without NS, respectively. Dot plots represent mean ± SEM.
See also Figure S5.
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Decoys and Overexpression Assays for miR-223 and miR-15a
For the decoy assay, we used the ‘‘tough decoy’’ (TuD) design previously
described (Mullokandov et al., 2012). Briefly, AB.pCCLsin.PPT.U6.hPGK.
GFP.wpre was used as a backbone vector with two target sites for miR-223
or miR-15a expressing EGFP to mark infected hiPSCs. Lentivirus production
and titration were performed as previously described (Mullokandov et al.,
2012). For themiR-223overexpression, we used the third-generation self-inac-
tivating lentiviral vector platform. The lentiviral vector (LV) encoded hsa-miR-
223 and a truncated nerve growth factor receptor (NGFR) as previously
described (Baccarini et al., 2011). hiPSCs were infected for 24 hr and sorted
3days later forGFP+andNGFR-PE+expression for thedecoy andoverexpres-
sion functional assays, respectively. These cells were cultured using the same
conditions as the original hiPSCs. The infected cells were differentiated, and
flow cytometry, GM-CSF sensitivity, and colony-formation assays were per-
formed and analyzed as described above. In sorted CD33+ cells treated with
decoys, RNAwas isolated andRT-PCRwas performed for target genes as pre-
viously described in Supplemental Experimental Procedures (‘‘Reverse Tran-
scription Quantitative and Conventional PCR Analysis’’ section).
Luciferase Assay in HEK293-miR-223 Cells
To analyze the regulation of the putative target FOXO3 andRAB12 bymiR-223,
we generated constructs using pMIR-Report-Vector. These vectors express
Firefly luciferase and the 30 UTR sequences of FOXO3 and RAB12 by miR-
223 (see sequence details in Table S5). We used the same vector without a
30 UTR as a negative control. The mutated binding site was generated
by directed mutagenesis as indicated the manufacture’s provider (Invitrogen).
1.5 3 105 HEK293T cells or HEK293T expressing constitutively miR-223 were
transfected with these constructs with Lipofectamine 2000 (Invitrogen). For
normalization, a plasmid encoding Renilla luciferase was included in the trans-
fection in each condition. Luciferase activity was detected with a Dual Lucif-
erase Reporter kit (Promega) 48 hr after transfection.
Statistical Analysis
For overlapping gene sets and correlation patterns between miRNAs and their
targets genes, p values were calculated from different permutation and statis-
tical approaches (n > = 10,000) to assess the overlap significance between
different gene sets. Additional statistical analyses were performed with Prism
5.0 (Graph Pad Software) using ANOVA and t test. p values < 0.05 were
considered statistically significant. The number of stars indicates the signifi-
cance level *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.09.019.
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